Corpus Intelligence IC Memo — STONESPRINGS HOSPITAL CENTER 2026-04-26 09:35 UTC
IC Memo — STONESPRINGS HOSPITAL CENTER
Investment Committee Memorandum | VA | 107 beds | Grade C | EBITDA uplift $6.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

STONESPRINGS HOSPITAL CENTER

CCN 490145 | LOUDOUN, VA | 107 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

STONESPRINGS HOSPITAL CENTER is a 107-bed suburban community hospital in LOUDOUN, VA with $94.3M in net patient revenue and a 15.1% operating margin. The hospital serves a payer mix of 19.6% Medicare, 2.0% Medicaid, and 78.3% commercial.

Thesis: Turnaround. Our ML models identify $6.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 15.1% to 22.5% (+736bps).

Net Revenue HCRIS$94.3M
Current EBITDA COMPUTED$14.3M
Operating Margin COMPUTED15.1%
Occupancy HCRIS22.9%
Revenue / Bed COMPUTED$881K
Net-to-Gross HCRIS22.0%
Distress Probability ML53.1%

2. Market Context & Competitive Position

111
VA Hospitals
4.4%
State Median Margin
52
Comparable Hospitals

VA has 111 Medicare-certified hospitals with a median operating margin of 4.4%. The target's margin of 15.1% places it above the state median. Among 52 size-comparable peers (54-214 beds), the median margin is 5.5%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (54-214), prioritizing same-state peers. 52 hospitals in the comp set.

HospitalStateBedsRevenueMargin
STONESPRINGS HOSPITAL CENTER (Target)VA107$94.3M15.1%
CHILDRENS HOSPITAL OF THE KINGVA202$546.2M-9.9%
INOVA LOUDOUN HOSPITAL CENTERVA189$510.3M22.9%
RESTON HOSPITALVA201$385.5M34.6%
INOVA FAIR OAKS HOSPITALVA174$382.5M28.5%
SENTARA MARTHA JEFFERSON HOSPIVA150$362.0M-6.4%
SENTARA PRINCESS ANNE HOSPITALVA174$361.5M10.3%
MARYVIEW HOSPITALVA160$348.0M-2.5%
ST. FRANCIS MEDICAL CENTERVA128$339.6M8.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $6.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.0M+210bp18mo
Cost to Collect4.5%2.5%$1.9M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.1M+122bp9mo
Clean Claim Rate88.0%96.0%$60K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.0M
Cost to Collect
$1.9M
Denial Rate Reduction
$1.9M
A/R Days Reduction
$1.1M
Clean Claim Rate
$60K
Total EBITDA Uplift$6.9M
Current EBITDA$14.3M
+ RCM Uplift+$6.9M
Pro Forma EBITDA$21.2M
Current Margin15.1%
Pro Forma Margin22.5%
WC Released (1x)$3.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$22.0M$163.6M7.45x49.4%
Base (11x exit)10.0x11.0x$22.0M$187.1M8.52x53.5%
Bull Case9.0x11.0x$19.8M$217.1M10.98x61.5%
Bull (12x exit)9.0x12.0x$19.8M$242.7M12.28x65.1%
Bear Case11.0x10.0x$24.2M$121.7M5.04x38.2%
Bear (11x exit)11.0x11.0x$24.2M$141.8M5.87x42.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 22.9%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 53.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 52 hospitals with 54-214 beds
  • Same-state prioritization (n=53)
  • Comp margins: P25=-8.0% / P50=5.5% / P75=17.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.